WO2006010283A1 - Prevention and treatment of thrombus formation - Google Patents

Prevention and treatment of thrombus formation Download PDF

Info

Publication number
WO2006010283A1
WO2006010283A1 PCT/CH2005/000423 CH2005000423W WO2006010283A1 WO 2006010283 A1 WO2006010283 A1 WO 2006010283A1 CH 2005000423 W CH2005000423 W CH 2005000423W WO 2006010283 A1 WO2006010283 A1 WO 2006010283A1
Authority
WO
WIPO (PCT)
Prior art keywords
histamine
receptor specific
specific antagonist
acute coronary
related diseases
Prior art date
Application number
PCT/CH2005/000423
Other languages
French (fr)
Inventor
Felix Tanner
Jan Steffel
Thomas F. Luscher
Original Assignee
Universität Zürich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Zürich filed Critical Universität Zürich
Publication of WO2006010283A1 publication Critical patent/WO2006010283A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • This invention relates to the prevention and treatment of thrombus formation using a histamine H 1 receptor antagonist.
  • Thrombus formation is the precipitating cause of diseases such as acute coronary syndromes, which comprises unstable angina, non-ST-segment-elevation myocardial infarction, or ST-segment-elevation myocardial infarction.
  • H 1 receptor antagonists block the histamine type 1 receptor. They are currently used mainly for the symptomatic treatment of allergic diseases such as urticaria, allergic rhinitis, or anaphylactic reactions.
  • mast cells which produce and release histamine have been found both in coronary atherectomy specimens as well as in the adventitia of infarct-related arteries. Both the presence of mast cells [Forman, M. B., et al., N Engl J Med, 1985. 313(18):1138-41] and an elevation of the plasma histamine concentration [Sakata, Y., et al., Am J Cardiol, 1996. 77(12): 1121-6] has been described in patients with variant angina. However, these findings so far have not implied that diseases such as variant angina and acute coronary syndromes should be treated by H-i receptor antagonists because a link between thrombus formation and histamine has not been known.
  • the central phenomenon in acute coronary syndromes is thrombus formation leading to vascular occlusion. All the established treatments for acute coronary syndromes target thrombus formation. There is a need for additional effective treatment and prevention of thrombus formation which would complement and expand the existing methods of treatment and prevention.
  • the present invention relates to a method of treating and/or preventing thrombus related diseases, such as variant angina, acute coronary syndromes, transient ischemic attack, brain stroke, peripheral arterial occlusive disease, and the like, comprising administering a histamine Hi receptor specific antagonist, and the use of histamine H 1 receptor specific antagonist in such a treatment and in the manufacture of medicaments for treating and/or preventing thrombus related diseases.
  • thrombus related diseases such as variant angina, acute coronary syndromes, transient ischemic attack, brain stroke, peripheral arterial occlusive disease, and the like.
  • This novel method of treatment and prevention is based on the findings that tissue factor initiating thrombus formation is induced by histamine.
  • Fig. 1 Histamine induces tissue factor (TF) expression in human aortic endothelial cells (HAEC) and human aortic vascular smooth muscle cells (HAVSMC).
  • TF tissue factor
  • Fig. 1A Concentration dependency of histamine induced TF expression in HAEC. Maximal TF expression is about 18x the basal expression with 10 "5 mol/l histamine.
  • X axis -log 10 concentration of histamine.
  • Y axis Values are given as n-fold increase of unstimulated control. (*) p ⁇ 0.02 compared to unstimulated control.
  • Y axis Values are given as percentage of TF expression at 5 hours.
  • Fig. 1 C Histamine and TF expression in HAVSMC. Histamine increases basal TF expression in HAVSMC 3-fold.
  • X axis His: + or - indicates presence or absence of 10 "5 mol/l histamine.
  • Y axis Values are given as n-fold increase of unstimulated control.
  • Fig. 2 Histamine induced increase in TF expression and TF surface activity in HAEC is completely inhibited by the H 1 receptor blocker mepyramine. Bars represent at least 4 different experiments; error bars represent standard error of the mean. Representative blots are shown; all blots are equalized to acetylated tubulin expression (aT).
  • Fig 2A Upper panel: Preincubation of HAEC with mepyramine (Me) completely prevents histamine (His) induced TF expression in a concentration dependent manner.
  • Me -logio concentration of mepyramine.
  • Y axis Values are given as percentage of TF expression with 10 "5 mol/l histamine only. (*) indicates significant decrease in TF expression as compared to stimulation with histamine (p ⁇ 0.0001).
  • X axis His: + or - indicates presence or absence of 10 "5 mol/l histamine.
  • ChI -logio concentration of chlorpheniramine
  • Di -logio concentration of diphenhydramine
  • Fig 2B Pretreatment of HAEC with cimetidine (Cim) does not affect histamine induced expression of TF.
  • X axis His: + or - indicates presence or absence of 10 "5 mol/l histamine.
  • Cim -logio concentration of cimetidine.
  • Y axis Values are given as percentage of TF expression with histamine only.
  • Fig. 2C Stimulation with histamine increases TF surface activity in HAEC. Increase in activity is completely suppressed by incubation with mepyramine (10 "5 mol/l).
  • X axis His: + or - indicates presence or absence of 10 "5 mol/l histamine.
  • Me + or - indicates presence or absence of 10 "5 mol/l mepyramine Y axis: Values are given as n-fold increase of unstimulated control.
  • Fig. 2D Pretreatment with mepyramine (10 "5 mol/l), but not cimetidine (10 ⁇ 5 mol/l), significantly reduces histamine-induced increase in TF expression in HAVSMC.
  • Me + or - indicates presence or absence of 10 "5 mol/l mepyramine.
  • Cim + or - indicates presence or absence of 10 "5 mol/l cimetidine.
  • Y axis Values are given as percentage of TF expression with histamine only.
  • the present invention relates to a method of treating thrombus related diseases comprising administering a histamine H-i receptor specific antagonist, and the use of histamine H 1 receptor specific antagonist in such a treatment and in the manufacture of medicaments for treating thrombus related diseases.
  • the present invention relates to a method of preventing thrombus related diseases, such as variant angina, acute coronary syndromes, transient ischemic attack, brain stroke, peripheral arterial occlusive disease, and the like, in particular variant angina and acute coronary syndromes, comprising administering a histamine H 1 receptor specific antagonist, and the use of histamine H 1 receptor specific antagonist in such a treatment and in the manufacture of medicaments for preventing thrombus related diseases.
  • thrombus related diseases such as variant angina, acute coronary syndromes, transient ischemic attack, brain stroke, peripheral arterial occlusive disease, and the like, in particular variant angina and acute coronary syndromes
  • administering a histamine H 1 receptor specific antagonist and the use of histamine H 1 receptor specific antagonist in such a treatment and in the manufacture of medicaments for preventing thrombus related diseases.
  • Thrombus related diseases considered are, for example, variant angina, acute coronary syndromes, transient ischemic attack, brain stroke, peripheral arterial occlusive disease, and the like, in particular variant angina and acute coronary syndromes.
  • Acute coronary syndromes comprise, for example, unstable angina, non-ST-segment-elevation myocardial infarction and ST-segment-elevation myocardial infarction.
  • Hi receptor specific antagonists are widely known. An extensive report may be found e.g. in Wolff, M. E., Ed., Burger's Medicinal Chemistry and Drug Discovery, 5 th edition, Vol. 5, John Wiley & Sons.
  • H 1 receptor specific antagonists are, for example, disclosed in patents EP-B-085 959, EP-B-133 534, EP-B-270 818, EP-B-271 192, US 2,712,020, US 4,254,129, US 4,727,076, US 4,837,325, and US 6,420,560.
  • H 1 receptor specific antagonists considered are, e.g., carbinoxamine, hydroxyzine, meclizine, promethazine, doxylamine, acrivastine, rupatadine, epinastine, fluticasone, mizolastine, ebastine, fexofenadine, cetirizine, levocetirizine, astemizole, loratidine, desloratidine, clemastine, dimetinden, chlorpheniramine, bropheniramine, terfenadine, oxatomide, azelastine, mepyramine (pyrilamine), or diphenhydramine.
  • the invention is not restricted to the mentioned H 1 receptor specific antagonists, but extends to all H 1 receptor specific antagonists.
  • Preferred H 1 receptor specific antagonists are the compound known as mepyramine, also named pyrilamine, N,N-dimethyl-N'-(4-methoxybenzyl)-N'-(2-pyridyl)ethylenediamine, e.g. applied as the maleate salt; chlorpheniramine, 2-p-chloro- ⁇ -(2-dimethylaminoethyl) benzyl]pyridine; e.g.
  • One aspect of the invention relates to a method of treating thrombus related diseases comprising administering a Hi receptor specific antagonist in a quantity effective against thrombus related diseases to a mammal in need thereof, for example to a human requiring such treatment.
  • the treatment may be for prophylactic or therapeutic purposes.
  • the H 1 receptor specific antagonist is preferably in the form of a pharmaceutical preparation comprising the H-i receptor specific antagonist in chemically pure form and optionally a pharmaceutically acceptable carrier and optionally adjuvants.
  • the Hi receptor specific antagonist is used in an amount effective against thrombus related diseases.
  • the dosage of the active ingredient depends upon the species, its age, weight, and individual condition, the individual pharmacokinetic data, the mode of administration, and whether the administration is for prophylactic or therapeutic purposes. In the case of an individual having a bodyweight of about 70 kg the daily dose administered is from approximately 1 mg to approximately 500 mg, preferably from approximately 1 mg to approximately 100 mg, of a H 1 receptor specific antagonist.
  • compositions for enteral administration such as nasal, buccal, rectal or, especially, oral administration, and for parenteral administration, such as intravenous, intramuscular or subcutaneous administration, are especially preferred.
  • the pharmaceutical compositions comprise from approximately 1% to approximately 95% active ingredient, preferably from approximately 20% to approximately 90% active ingredient.
  • compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, viscosity-increasing agents, salts for regulating osmotic pressure and/or buffers and are prepared in a manner known per se, for example by means of conventional dissolving and lyophilizing processes.
  • suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, and also binders, such as starches, cellulose derivatives and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, flow conditioners and lubricants, for example stearic acid or salts thereof and/or polyethylene glycol.
  • Tablet cores can be provided with suitable, optionally enteric, coatings. Dyes or pigments may be added to the tablets or tablet coatings, for example for identification purposes or to indicate different doses of active ingredient.
  • compositions for oral administration also include hard capsules consisting of gelatin, and also soft, sealed capsules consisting of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the capsules may contain the active ingredient in the form of granules, or dissolved or suspended in suitable liquid excipients, such as in oils.
  • Transdermal application is also considered, for example using a transdermal patch, which allows administration over an extended period of time, e.g. from one to twenty days.
  • Another aspect of the invention relates to the use of H 1 receptor specific antagonists in the treatment of thrombus related diseases and in the manufacture of medicaments for treating thrombus related diseases.
  • Such medicaments are manufactured by methods known in the art, especially conventional mixing, coating, granulating, dissolving or lyophilizing.
  • a H 1 receptor specific antagonist can be administered alone or in combination with one or more other therapeutic agents, possible combination therapy taking the form of fixed combinations of a Hi receptor specific antagonist and one or more other therapeutic agents known in the treatment of thrombus related diseases, the administration being staggered or given independently of one another, or being in the form of a fixed combination.
  • Possible combination partners considered are aspirin, clopidogrel or other inhibitors of platelet aggregation, heparin or other inactivators of coagulation factors, GPIIbIIIa antagonists such as abciximab, eptifibatide or tirofiban, beta blockers, ACE inhibitors, HMG-CoA-reductase inhibitors, or related compounds.
  • Tissue Factor a 263 residue membrane-bound glycoprotein
  • ACS acute coronary syndromes
  • histamine induces TF expression and TF activity in cultured human aortic endothelial cells (HAEC) and human aortic vascular smooth muscle cells (HAVSMC). This effect is completely abolished by a H-i receptor antagonist, e.g. by mepyramine.
  • Augmented TF expression in HAEC and HAVSMC after stimulation with histamine is consistent with atherosclerosis as an inflammatory disease.
  • histamine induced TF expression may represent an important link between vascular inflammation and thrombus formation.
  • histamine evokes potent vascular contractions through activation of the Hi receptor [Okumura, K., et al., J Am Coll Cardiol, 1991. 17(2):338-45].
  • histamine induced vasospasm and initiation of thrombus formation are both mediated through the same receptor.
  • the H-i receptor antagonist mepyramine completely inhibits the histamine induced increase in TF expression and surface activity.
  • HAEC and HA VSMC are cultured using the procedure described [Eto, M., et al., Circulation, 2002. 105(15): 1756-9].
  • Cells are grown to confluence in 6 cm culture dishes and rendered quiescent for 24 hours before stimulation with histamine.
  • Mepyramine and cimetidine both from Sigma, Germany are added to the dishes 30 minutes prior to stimulation.
  • TF protein expression is determined by Western Blot analysis as described by Eto et al. [loc. cit.].
  • An antibody to human TF American Diagnostica
  • All blots are normalized to tubulin expression (anti-acetylated tubulin, 1 :5000 dilution, Sigma).
  • TF surface activity is analyzed with a commercially available kit
  • LDH lactate dehydrogenase
  • TF expression is enhanced in HAVSMC after stimulation with histamine; maximal increase is about 3-fold as compared to control conditions (Fig. 1C). Histamine is known to exert most of its actions on cells through the Hi and / or H 2 receptor.
  • the cells are pretreated with mepyramine or cimetidine to block the H-i and H 2 receptor, respectively.
  • Pretreatment with mepyramine completely abolishes histamine induced TF expression in HAEC (Fig. 2A) while it is not affected by cimetidine (Fig. 2B).
  • Preincubation with chlorpheniramine and diphenhydramine, two other selective Hi receptor antagonists equally prevents histamine induced TF expression in HAEC (Fig. 2A).
  • histamine induced increase in TF surface activity is completely inhibited by mepyramine (Fig. 2C).
  • Biologically active TF is located at the cell surface.
  • the increase in histamine induced expression of TF in HAEC is indeed paralleled by an increased TF surface activity.
  • the relative increase of the latter is less pronounced as the increase in total protein expression.
  • the distribution of TF in several cellular compartments as well as the expression of encrypted TF at the cell surface might account for this difference [Rao, L.V. and Pendurthi, U. R., Blood Coagul Fibrinolysis, 1998. 9 Suppl 1 :S27-35].
  • vascular smooth muscle cells display a basal expression of TF. This may assure the rapid formation of a localized nidus of coagulation following endothelial denudation.
  • this basal expression might account for the observation that maximal TF expression after stimulation with histamine results in a 3- fold increase above basal expression in HAVSMC, while the increase is much more pronounced in HAEC.

Abstract

The invention relates to a method of treating thrombus related diseases, such as variant angina, acute coronary syndromes, transient ischemic attack, brain stroke, peripheral arterial occlusive disease, and the like, comprising administering a histamine H1, receptor specific antagonist, and the use of histamine H1, receptor specific antagonists in such a treatment and in the manufacture of medicaments for treating thrombus related diseases. The invention is based on the fact that tissue factor initiating thrombus formation is induced by histamine.

Description

Prevention and treatment of thrombus formation
Field of the invention
This invention relates to the prevention and treatment of thrombus formation using a histamine H1 receptor antagonist.
Background of the invention
Thrombus formation is the precipitating cause of diseases such as acute coronary syndromes, which comprises unstable angina, non-ST-segment-elevation myocardial infarction, or ST-segment-elevation myocardial infarction.
Current treatment of thrombus formation, e.g. in acute coronary syndrome, consist in administering aspirin (inhibition of platelet aggregation), clopidogrel (inhibition of platelet aggregation), heparin (inactivation of coagulation factors), glycoprotein llb/llla (GPIIbIIIa) antagonists such as abciximab or eptifibatide (inhibition of platelet aggregation), or related compounds. Combination of all these mentioned drugs is more effective than administering each of them separately. Typically such combination is given to a patient with acute coronary syndrome.
H1 receptor antagonists block the histamine type 1 receptor. They are currently used mainly for the symptomatic treatment of allergic diseases such as urticaria, allergic rhinitis, or anaphylactic reactions.
Mast cells, which produce and release histamine have been found both in coronary atherectomy specimens as well as in the adventitia of infarct-related arteries. Both the presence of mast cells [Forman, M. B., et al., N Engl J Med, 1985. 313(18):1138-41] and an elevation of the plasma histamine concentration [Sakata, Y., et al., Am J Cardiol, 1996. 77(12): 1121-6] has been described in patients with variant angina. However, these findings so far have not implied that diseases such as variant angina and acute coronary syndromes should be treated by H-i receptor antagonists because a link between thrombus formation and histamine has not been known.
Inflammation is involved in the pathogenesis of acute coronary syndromes as it can induce rupture of atherosclerotic plaques. According to the current recommendations by the Swiss Society of Cardiology, the role of inflammation in acute coronary syndromes is not clear enough to justify a general anti-inflammatory treatment. Singh, M., et al. [J Cardiovasc Pharmacol Then, 2003 June. 8(2): 135-48] propose to use histamine H1 receptor antagonists to impair the intense inflammatory reaction following reperfusion of ischemic myocardium. However, the authors did not recognize nor mention the usefulness of histamine H-i receptor antagonists for preventing and treating thrombus formation in acute coronary syndromes and variant angina.
The central phenomenon in acute coronary syndromes is thrombus formation leading to vascular occlusion. All the established treatments for acute coronary syndromes target thrombus formation. There is a need for additional effective treatment and prevention of thrombus formation which would complement and expand the existing methods of treatment and prevention.
Summary of the invention
The present invention relates to a method of treating and/or preventing thrombus related diseases, such as variant angina, acute coronary syndromes, transient ischemic attack, brain stroke, peripheral arterial occlusive disease, and the like, comprising administering a histamine Hi receptor specific antagonist, and the use of histamine H1 receptor specific antagonist in such a treatment and in the manufacture of medicaments for treating and/or preventing thrombus related diseases.
This novel method of treatment and prevention is based on the findings that tissue factor initiating thrombus formation is induced by histamine.
Brief description of the Figures
Fig. 1 : Histamine induces tissue factor (TF) expression in human aortic endothelial cells (HAEC) and human aortic vascular smooth muscle cells (HAVSMC).
Bars represent at least 4 different experiments; error bars represent standard error of the mean. Representative blots are shown; all blots are equalized to acetylated tubulin expression (aT).
Fig. 1A: Concentration dependency of histamine induced TF expression in HAEC. Maximal TF expression is about 18x the basal expression with 10"5 mol/l histamine.
X axis: -log10 concentration of histamine. Y axis: Values are given as n-fold increase of unstimulated control. (*) p < 0.02 compared to unstimulated control.
Fig. 1 B: Time dependency of TF expression in HAEC after stimulation with histamine. TF induction is maximal after 5 hours of stimulation (n=3). X axis: hours of stimulation.
Y axis: Values are given as percentage of TF expression at 5 hours.
Fig. 1 C: Histamine and TF expression in HAVSMC. Histamine increases basal TF expression in HAVSMC 3-fold.
X axis: His: + or - indicates presence or absence of 10"5 mol/l histamine. Y axis: Values are given as n-fold increase of unstimulated control.
(*) indicates significant increase in TF expression as compared to control (p < 0.05).
Fig. 2: Histamine induced increase in TF expression and TF surface activity in HAEC is completely inhibited by the H1 receptor blocker mepyramine. Bars represent at least 4 different experiments; error bars represent standard error of the mean. Representative blots are shown; all blots are equalized to acetylated tubulin expression (aT).
Fig 2A: Upper panel: Preincubation of HAEC with mepyramine (Me) completely prevents histamine (His) induced TF expression in a concentration dependent manner. X axis: His: + or - indicates presence or absence of 10'5 mol/l histamine.
Me: -logio concentration of mepyramine.
Y axis: Values are given as percentage of TF expression with 10"5 mol/l histamine only. (*) indicates significant decrease in TF expression as compared to stimulation with histamine (p < 0.0001). Middle and lower panel: Histamine induced TF expression in HAEC is suppressed in a similar manner after preincubation with the selective Hi receptor blockers chlorpheniramine (ChI, n=2) and diphenhydramine (Di, n=2).
X axis: His: + or - indicates presence or absence of 10"5 mol/l histamine.
ChI: -logio concentration of chlorpheniramine Di: -logio concentration of diphenhydramine
Fig 2B: Pretreatment of HAEC with cimetidine (Cim) does not affect histamine induced expression of TF.
X axis: His: + or - indicates presence or absence of 10"5 mol/l histamine.
Cim: -logio concentration of cimetidine. Y axis: Values are given as percentage of TF expression with histamine only. Fig. 2C: Stimulation with histamine increases TF surface activity in HAEC. Increase in activity is completely suppressed by incubation with mepyramine (10"5 mol/l).
X axis: His: + or - indicates presence or absence of 10"5 mol/l histamine.
Me: + or - indicates presence or absence of 10"5 mol/l mepyramine Y axis: Values are given as n-fold increase of unstimulated control.
(*) p < 0.01 as compared to control; (#) p < 0.01 as compared to stimulation with histamine.
Fig. 2D: Pretreatment with mepyramine (10"5 mol/l), but not cimetidine (10~5 mol/l), significantly reduces histamine-induced increase in TF expression in HAVSMC. X axis: His: + or - indicates presence or absence of 10~5 mol/l histamine.
Me: + or - indicates presence or absence of 10"5 mol/l mepyramine.
Cim: + or - indicates presence or absence of 10"5 mol/l cimetidine.
Y axis: Values are given as percentage of TF expression with histamine only.
(*) p < 0.0001 as compared to control; (#) p < 0.0001 as compared to stimulation with histamine.
Detailed description of the invention
The present invention relates to a method of treating thrombus related diseases comprising administering a histamine H-i receptor specific antagonist, and the use of histamine H1 receptor specific antagonist in such a treatment and in the manufacture of medicaments for treating thrombus related diseases.
Likewise the present invention relates to a method of preventing thrombus related diseases, such as variant angina, acute coronary syndromes, transient ischemic attack, brain stroke, peripheral arterial occlusive disease, and the like, in particular variant angina and acute coronary syndromes, comprising administering a histamine H1 receptor specific antagonist, and the use of histamine H1 receptor specific antagonist in such a treatment and in the manufacture of medicaments for preventing thrombus related diseases.
Thrombus related diseases considered are, for example, variant angina, acute coronary syndromes, transient ischemic attack, brain stroke, peripheral arterial occlusive disease, and the like, in particular variant angina and acute coronary syndromes. Acute coronary syndromes comprise, for example, unstable angina, non-ST-segment-elevation myocardial infarction and ST-segment-elevation myocardial infarction. Hi receptor specific antagonists are widely known. An extensive report may be found e.g. in Wolff, M. E., Ed., Burger's Medicinal Chemistry and Drug Discovery, 5th edition, Vol. 5, John Wiley & Sons. H1 receptor specific antagonists are, for example, disclosed in patents EP-B-085 959, EP-B-133 534, EP-B-270 818, EP-B-271 192, US 2,712,020, US 4,254,129, US 4,727,076, US 4,837,325, and US 6,420,560. H1 receptor specific antagonists considered are, e.g., carbinoxamine, hydroxyzine, meclizine, promethazine, doxylamine, acrivastine, rupatadine, epinastine, fluticasone, mizolastine, ebastine, fexofenadine, cetirizine, levocetirizine, astemizole, loratidine, desloratidine, clemastine, dimetinden, chlorpheniramine, bropheniramine, terfenadine, oxatomide, azelastine, mepyramine (pyrilamine), or diphenhydramine. However, the invention is not restricted to the mentioned H1 receptor specific antagonists, but extends to all H1 receptor specific antagonists.
Preferred H1 receptor specific antagonists are the compound known as mepyramine, also named pyrilamine, N,N-dimethyl-N'-(4-methoxybenzyl)-N'-(2-pyridyl)ethylenediamine, e.g. applied as the maleate salt; chlorpheniramine, 2-p-chloro-α-(2-dimethylaminoethyl) benzyl]pyridine; e.g. applied as the maleate salt; diphenhydramine, 2-diphenylmethoxy- N.N-dimethyl-ethylamine, preferably as the hydrochloride; cetirizine, [2-[4-[4- (chlorophenyOphenylmethyrj-i-piperazinylJethoxyjacetic acid; loratidine, ethyl 4-(8-chloro- 5,6-dihydro-11 H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 -ylidene)-1 -piperidinecarboxylate; clemastine, (+)(2R)-2-[2-[(R)-p-chloro-α-methyl-α-phenylbenzyl-1 -oxy]ethyl]-1 - methylpyrrolidine, preferably as the fumarate salt; and dimetinden, N,N-dimethyl-3-[1-(2- pyridyl)ethyl]inden-2-ethylamine, e.g. applied as the maleate salt. Particularly preferred are chlorpheniramine, diphenhydramine, cetirizine, loratidine, clemastine, and dimetinden.
One aspect of the invention relates to a method of treating thrombus related diseases comprising administering a Hi receptor specific antagonist in a quantity effective against thrombus related diseases to a mammal in need thereof, for example to a human requiring such treatment. The treatment may be for prophylactic or therapeutic purposes. For the administration, the H1 receptor specific antagonist is preferably in the form of a pharmaceutical preparation comprising the H-i receptor specific antagonist in chemically pure form and optionally a pharmaceutically acceptable carrier and optionally adjuvants. The Hi receptor specific antagonist is used in an amount effective against thrombus related diseases. The dosage of the active ingredient depends upon the species, its age, weight, and individual condition, the individual pharmacokinetic data, the mode of administration, and whether the administration is for prophylactic or therapeutic purposes. In the case of an individual having a bodyweight of about 70 kg the daily dose administered is from approximately 1 mg to approximately 500 mg, preferably from approximately 1 mg to approximately 100 mg, of a H1 receptor specific antagonist.
Pharmaceutical compositions for enteral administration, such as nasal, buccal, rectal or, especially, oral administration, and for parenteral administration, such as intravenous, intramuscular or subcutaneous administration, are especially preferred. The pharmaceutical compositions comprise from approximately 1% to approximately 95% active ingredient, preferably from approximately 20% to approximately 90% active ingredient.
For parenteral administration including intracoronary, intracerebrovascular, or peripheral vascular injection/infusion preference is given to the use of solutions of the H1 receptor specific antagonist, and also suspensions or dispersions, especially isotonic aqueous solutions, dispersions or suspensions which, for example, can be made up shortly before use. The pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, viscosity-increasing agents, salts for regulating osmotic pressure and/or buffers and are prepared in a manner known per se, for example by means of conventional dissolving and lyophilizing processes.
For oral pharmaceutical preparations suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, and also binders, such as starches, cellulose derivatives and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, flow conditioners and lubricants, for example stearic acid or salts thereof and/or polyethylene glycol. Tablet cores can be provided with suitable, optionally enteric, coatings. Dyes or pigments may be added to the tablets or tablet coatings, for example for identification purposes or to indicate different doses of active ingredient. Pharmaceutical compositions for oral administration also include hard capsules consisting of gelatin, and also soft, sealed capsules consisting of gelatin and a plasticizer, such as glycerol or sorbitol. The capsules may contain the active ingredient in the form of granules, or dissolved or suspended in suitable liquid excipients, such as in oils. Transdermal application is also considered, for example using a transdermal patch, which allows administration over an extended period of time, e.g. from one to twenty days.
Another aspect of the invention relates to the use of H1 receptor specific antagonists in the treatment of thrombus related diseases and in the manufacture of medicaments for treating thrombus related diseases. Such medicaments are manufactured by methods known in the art, especially conventional mixing, coating, granulating, dissolving or lyophilizing.
A H1 receptor specific antagonist can be administered alone or in combination with one or more other therapeutic agents, possible combination therapy taking the form of fixed combinations of a Hi receptor specific antagonist and one or more other therapeutic agents known in the treatment of thrombus related diseases, the administration being staggered or given independently of one another, or being in the form of a fixed combination.
Possible combination partners considered are aspirin, clopidogrel or other inhibitors of platelet aggregation, heparin or other inactivators of coagulation factors, GPIIbIIIa antagonists such as abciximab, eptifibatide or tirofiban, beta blockers, ACE inhibitors, HMG-CoA-reductase inhibitors, or related compounds.
Tissue Factor (TF), a 263 residue membrane-bound glycoprotein, is a key enzyme for initiation and propagation of thrombus formation; indeed, it is thought to play a pivotal role in acute coronary syndromes (ACS) [Moons, A.H., Levi, M. and Peters, R.J., Cardiovasc Res, 2002. 53(2):313-25]. The present invention is based on the observation that histamine induces TF expression and TF activity in cultured human aortic endothelial cells (HAEC) and human aortic vascular smooth muscle cells (HAVSMC).This effect is completely abolished by a H-i receptor antagonist, e.g. by mepyramine.
Augmented TF expression in HAEC and HAVSMC after stimulation with histamine is consistent with atherosclerosis as an inflammatory disease. Indeed, histamine induced TF expression may represent an important link between vascular inflammation and thrombus formation. Further, histamine evokes potent vascular contractions through activation of the Hi receptor [Okumura, K., et al., J Am Coll Cardiol, 1991. 17(2):338-45]. Hence, histamine induced vasospasm and initiation of thrombus formation are both mediated through the same receptor. The H-i receptor antagonist mepyramine completely inhibits the histamine induced increase in TF expression and surface activity. Taken together, these findings point to a previously unrecognized link between inflammation, vasospasm, and thrombus formation, and form the basis of the treatment and/or prevention of variant angina and acute coronary syndromes according to the invention.
Examples
HAEC and HA VSMC are cultured using the procedure described [Eto, M., et al., Circulation, 2002. 105(15): 1756-9]. Cells are grown to confluence in 6 cm culture dishes and rendered quiescent for 24 hours before stimulation with histamine. Mepyramine and cimetidine (both from Sigma, Germany) are added to the dishes 30 minutes prior to stimulation. TF protein expression is determined by Western Blot analysis as described by Eto et al. [loc. cit.]. An antibody to human TF (American Diagnostica) is used at 1 :1000 dilution. All blots are normalized to tubulin expression (anti-acetylated tubulin, 1 :5000 dilution, Sigma). TF surface activity is analyzed with a commercially available kit
(American Diagnostica) according to the manufacturer's recommendations with some modifications as described [Cui, M. Z., et al., Arterioscler Thromb Vase Biol, 2003. 23(2):224-30]. A colorimetric assay for the detection of lactate dehydrogenase (LDH) is used according to the manufacturer's recommendations (Roche, Germany). Data are presented as mean +/- standard error of the mean. Unpaired t test is applied for comparison of two groups, ANOVA with Bonferroni correction for three or more groups. A p value < 0.05 is considered significant.
Stimulation of HAEC with histamine leads to a concentration- and time-dependent induction of TF expression up to 18-fold the basal level; maximal effects were observed after stimulation with 10"5 mol/l histamine (Fig. 1A) for 5 hours (Fig. 1 B). Further, the increase in total TF protein expression in response to stimulation with histamine is reflected in a 4-fold increase in TF surface activity after 5 hours of stimulation with 10~5 mol/l histamine (Fig. 2C). Similarly, TF expression is enhanced in HAVSMC after stimulation with histamine; maximal increase is about 3-fold as compared to control conditions (Fig. 1C). Histamine is known to exert most of its actions on cells through the Hi and / or H2 receptor. To determine the receptor involved in histamine-induced TF expression, the cells are pretreated with mepyramine or cimetidine to block the H-i and H2 receptor, respectively. Pretreatment with mepyramine completely abolishes histamine induced TF expression in HAEC (Fig. 2A) while it is not affected by cimetidine (Fig. 2B). Preincubation with chlorpheniramine and diphenhydramine, two other selective Hi receptor antagonists, equally prevents histamine induced TF expression in HAEC (Fig. 2A). Similarly, histamine induced increase in TF surface activity is completely inhibited by mepyramine (Fig. 2C). Pretreatment of histamine stimulated HAVSMC with mepyramine, but not cimetidine, significantly reduces TF expression (Fig. 2D). No cytotoxic effect of histamine, cimetidine, mepyramine, chlorpheniramine or diphenhydramine is observed at the concentrations used as measured by LDH-release into the cell supernatant (data not shown).
Biologically active TF is located at the cell surface. The increase in histamine induced expression of TF in HAEC is indeed paralleled by an increased TF surface activity. The relative increase of the latter is less pronounced as the increase in total protein expression. The distribution of TF in several cellular compartments as well as the expression of encrypted TF at the cell surface might account for this difference [Rao, L.V. and Pendurthi, U. R., Blood Coagul Fibrinolysis, 1998. 9 Suppl 1 :S27-35]. In contrast to unstimulated endothelial cells, vascular smooth muscle cells display a basal expression of TF. This may assure the rapid formation of a localized nidus of coagulation following endothelial denudation. Although clearly inducible, this basal expression might account for the observation that maximal TF expression after stimulation with histamine results in a 3- fold increase above basal expression in HAVSMC, while the increase is much more pronounced in HAEC.

Claims

Claims
1. Use of a histamine H1 receptor specific antagonist for the manufacture of a medicament for treating and/or preventing thrombus related diseases.
2. Use according to claim 1 wherein the thrombus related disease is variant angina, acute coronary syndrome, transient ischemic attack, brain stroke, peripheral arterial occlusive disease, and the like.
3. Use according to claim 1 wherein the thrombus related disease is variant angina or acute coronary syndrome.
4. Use according to claim 1 wherein the histamine H1 receptor specific antagonist is selected from the group consisting of carbinoxamine, hydroxyzine, meclizine, promethazine, doxylamine, acrivastine, rupatadine, epinastine, fluticasone, mizolastine, ebastine, fexofenadine, cetirizine, levocetirizine, astemizole, loratidine, desloratidine, clemastine, dimetinden, chlorpheniramine, bropheniramine, terfenadine, oxatomide, azelastine, mepyramine (pyrilamine), and diphenhydramine.
5. Use according to claim 1 wherein the histamine H-i receptor specific antagonist is selected from the group consisting of chlorpheniramine, diphenhydramine, cetirizine, loratidine, clemastine, and dimetinden.
6. A method of treating and/or preventing thrombus related diseases in a mammal comprising administering a therapeutically effective amount of a histamine H1 receptor specific antagonist to a mammal in need thereof.
7. The method of claim 6 wherein the histamine H1 receptor specific antagonist is administered in a combination with other pharmaceuticals useful in the treatment of thrombus related diseases.
8. The method of claim 6 for treating variant angina or acute coronary syndrome.
9. The method of claim 6 for preventing variant angina or acute coronary syndrome.
10. Use of a histamine H-i receptor specific antagonist in a method of treating and/or preventing thrombus related diseases.
PCT/CH2005/000423 2004-07-28 2005-07-19 Prevention and treatment of thrombus formation WO2006010283A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04405481.5 2004-07-28
EP04405481 2004-07-28

Publications (1)

Publication Number Publication Date
WO2006010283A1 true WO2006010283A1 (en) 2006-02-02

Family

ID=34979124

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CH2005/000423 WO2006010283A1 (en) 2004-07-28 2005-07-19 Prevention and treatment of thrombus formation

Country Status (1)

Country Link
WO (1) WO2006010283A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120136007A1 (en) * 2009-05-14 2012-05-31 The General Hospital Corporation Methods and compositions for treating degenerative and ischemic disorders
US20150352104A1 (en) * 2013-03-13 2015-12-10 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
US9669026B2 (en) 2013-03-13 2017-06-06 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
US9669025B2 (en) 2013-03-13 2017-06-06 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
US9925183B2 (en) 2014-09-15 2018-03-27 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
US11332459B2 (en) 2017-10-19 2022-05-17 Teijin Pharma Limited Benzimidazole derivatives and their uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010006971A1 (en) * 1999-08-20 2001-07-05 William Kreutner Methods for the treatment of vascular disorders
US20030187021A1 (en) * 2001-10-16 2003-10-02 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US20030220347A1 (en) * 1999-03-26 2003-11-27 Ucb S.A. Compounds and methods for treatment of asthma, allergy and inflammatory disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220347A1 (en) * 1999-03-26 2003-11-27 Ucb S.A. Compounds and methods for treatment of asthma, allergy and inflammatory disorders
US20010006971A1 (en) * 1999-08-20 2001-07-05 William Kreutner Methods for the treatment of vascular disorders
US20030187021A1 (en) * 2001-10-16 2003-10-02 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
COEUGNIET E: "DRUGS WITH ANTI THROMBOTIC EFFECT EXPERIMENTAL STUDY", THROMBOSIS AND HAEMOSTASIS, vol. 35, no. 2, 1976, pages 495 - 499, XP009055205, ISSN: 0340-6245 *
DAVIS J W ET AL: "Failure of diphenhydramine hydrochloride to prevent thrombosis at sites of endarterectomy in dogs", JOURNAL OF INTERNATIONAL MEDICAL RESEARCH 1978 UNITED KINGDOM, vol. 6, no. 1, 1978, pages 1 - 3, XP009055183 *
HIROKAWA K ET AL: "Up-regulation of thrombomodulin by activation of histamine H1-receptors in human umbilical-vein endothelial cells in vitro.", THE BIOCHEMICAL JOURNAL. 15 JUN 1991, vol. 276 ( Pt 3), 15 June 1991 (1991-06-15), pages 739 - 743, XP002349137, ISSN: 0264-6021 *
JANCINOVA VIERA ET AL: "Decreased arachidonic acid liberation participates in the anti-aggregatory effect of the histamine H1-receptor antagonist Bromadryl", PLATELETS (ABINGDON), vol. 10, no. 6, 1999, pages 391 - 398, XP009055201, ISSN: 0953-7104 *
LINDENMAIER H L ET AL: "[Successful therapy of a severe dextran incident using histamin H1- and H2-receptor blockaders]", DER CHIRURG; ZEITSCHRIFT FUR ALLE GEBIETE DER OPERATIVEN MEDIZEN. AUG 1978, vol. 49, no. 8, August 1978 (1978-08-01), pages 514 - 516, XP009055115, ISSN: 0009-4722 *
MICHAL F ET AL: "INHIBITION OF SEROTONIN 5 HYDROXY TRYPTAMINE INDUCED PLATELET AGGREGATION IN RELATION TO THROMBUS PRODUCTION IMIPRAMINE CHLORPROMAZINE DIPHENHYDRAMINE ATROPINE 1 HYOSCYAMINE HOMATROPINE ATP 2 BROMO LYSERGIC-ACID DI ETHYLAMIDE HYOSCINE HEMATOL SHEEP", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 166, no. 2, 1969, pages 276 - 284, XP009055204, ISSN: 0022-3565 *
NEMMAR ABDERRAHIM ET AL: "Pulmonary inflammation and thrombogenicity caused by diesel particles in hamsters: Role of histamine.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 168, no. 11, 1 December 2003 (2003-12-01), pages 1366 - 1372, XP002349136, ISSN: 1073-449X *
ROBERTS P S ET AL: "THE EFFECTS OF DIPHENHYDRAMINE BENADRYL ON BLOOD CLOTTING ENZYMES AND TESTS", VIRGINIA JOURNAL OF SCIENCE, vol. 24, no. 3, 1973, pages 166, XP001207491, ISSN: 0042-658X *
ROBERTSON R M ET AL: "Chronic recurrent angina.", SOUTHERN MEDICAL JOURNAL. OCT 1979, vol. 72, no. 10, October 1979 (1979-10-01), pages 1297 - 1299 , 13, XP009055114, ISSN: 0038-4348 *
STEFFEL JAN ET AL: "Histamine induces tissue factor expression - Implications for acute coronary syndromes", CIRCULATION, vol. 112, no. 3, July 2005 (2005-07-01), pages 341 - 349, XP002347192, ISSN: 0009-7322 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9399032B2 (en) * 2009-05-14 2016-07-26 The General Hospital Corporation Methods and compositions for treating degenerative and ischemic disorders
US10322122B2 (en) 2009-05-14 2019-06-18 The General Hospital Corporation Methods and compositions for treating degenerative and ischemic disorders
US20120136007A1 (en) * 2009-05-14 2012-05-31 The General Hospital Corporation Methods and compositions for treating degenerative and ischemic disorders
US9522148B2 (en) * 2013-03-13 2016-12-20 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
US11103500B2 (en) 2013-03-13 2021-08-31 IRR, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
US9669026B2 (en) 2013-03-13 2017-06-06 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
US9669025B2 (en) 2013-03-13 2017-06-06 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
CN105517631A (en) * 2013-03-13 2016-04-20 炎症反应研究公司 Use of levocetirizine and montelukast in the treatment of traumatic injury
US9937166B2 (en) 2013-03-13 2018-04-10 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
US11344545B2 (en) 2013-03-13 2022-05-31 IRR, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
US10201537B2 (en) 2013-03-13 2019-02-12 IRR, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
US10206919B2 (en) 2013-03-13 2019-02-19 IRR, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
US20150352104A1 (en) * 2013-03-13 2015-12-10 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
US20220096465A1 (en) * 2013-03-13 2022-03-31 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
US9925183B2 (en) 2014-09-15 2018-03-27 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
US10792281B2 (en) 2014-09-15 2020-10-06 IRR, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
US10195193B2 (en) 2014-09-15 2019-02-05 IRR, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
US11590125B2 (en) 2014-09-15 2023-02-28 IRR, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
US11332459B2 (en) 2017-10-19 2022-05-17 Teijin Pharma Limited Benzimidazole derivatives and their uses

Similar Documents

Publication Publication Date Title
AU2017258834B2 (en) Multisubstituted aromatic compounds as serine protease inhibitors
US20130172324A1 (en) Method for treating cardiovascular diseases using rho kinase inhibitor compounds
WO2006010283A1 (en) Prevention and treatment of thrombus formation
US20080039391A1 (en) New Indications for Direct Thrombin Inhibitors in the Cardiovascular Field
TWI373335B (en) Pharmaceutical composition for therapeutic treatment of arteriosclerosi and hypertension
EP1940399A2 (en) Use of par-i/par- 4 inhibitors for treating or preventing vascular diseases
EP2400969A1 (en) Method for treating pulmonary diseases using rho kinase inhibitor compounds
BRPI0608656A2 (en) pharmaceutical compositions for treating thrombosis
Patil et al. Pyridine and its biological activity: a review
WO2004105757A2 (en) Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
JP2009543843A (en) New indications for direct thrombin inhibitors
SK287012B6 (en) Pharmaceutical composition comprising cyclopeptide, use of the composition or cyclopeptide for the preparation of a medicament and set containing thereof
US20110015129A1 (en) New paediatric indications for direct thrombin inhibitors
WO2013068909A1 (en) N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
CN103648492A (en) Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors
US6979687B1 (en) Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities
JP5045442B2 (en) Benzene derivative or its salt
AU2005314810B2 (en) Method for reduction, stabilization and prevention of rupture of lipid rich plaque
KR101386697B1 (en) Composition for preventing or treating vascular permeability disease comprising imatinib or pharmaceutically acceptable salts thereof as active ingredient
US20090062338A1 (en) Nitroxides for use in treating or preventing cardiovascular disease
US20080139614A1 (en) Treatment Of Stroke With Histamine H3 Inverse Agonists Or Histamine H3 Antagonists
JP2020520948A (en) Novel use of formyl peptide receptor 2/lipoxin A4 receptor (FPR2/ALX) agonists for the treatment of heart failure
CN111670188B (en) Compounds and compositions for treating fibrosis
CN114072205A (en) Method of treating hypertension with TIE-2 activator
Andrikopoulos et al. Ivabradine: a selective if current inhibitor in the treatment of stable angina

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase